NORTHSTAR ASSET MANAGEMENT Co LLC Sells 5,810 Shares of Danaher Corporation (NYSE:DHR)

NORTHSTAR ASSET MANAGEMENT Co LLC decreased its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 14.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,185 shares of the conglomerate's stock after selling 5,810 shares during the period. Danaher accounts for about 1.6% of NORTHSTAR ASSET MANAGEMENT Co LLC's investment portfolio, making the stock its 13th largest holding. NORTHSTAR ASSET MANAGEMENT Co LLC's holdings in Danaher were worth $6,803,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Catawba River Capital lifted its position in shares of Danaher by 2.1% during the 1st quarter. Catawba River Capital now owns 28,711 shares of the conglomerate's stock valued at $5,886,000 after acquiring an additional 594 shares during the last quarter. Concurrent Investment Advisors LLC lifted its holdings in shares of Danaher by 193.2% during the first quarter. Concurrent Investment Advisors LLC now owns 10,048 shares of the conglomerate's stock valued at $2,060,000 after purchasing an additional 6,621 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the period. World Investment Advisors increased its stake in Danaher by 13.8% in the 1st quarter. World Investment Advisors now owns 15,879 shares of the conglomerate's stock worth $3,255,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Wayfinding Financial LLC purchased a new stake in Danaher during the first quarter valued at about $104,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.20% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on DHR. Evercore ISI cut their price target on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a report on Tuesday, April 22nd. Bank of America reduced their target price on Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Deutsche Bank Aktiengesellschaft decreased their target price on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. The Goldman Sachs Group reduced their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Stock Performance

NYSE:DHR traded down $2.64 during midday trading on Monday, reaching $200.56. The stock had a trading volume of 836,293 shares, compared to its average volume of 3,489,300. The stock has a market capitalization of $143.53 billion, a P/E ratio of 38.96, a PEG ratio of 2.85 and a beta of 0.77. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The firm's fifty day simple moving average is $195.63 and its 200-day simple moving average is $207.10.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. On average, equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.64%. Danaher's dividend payout ratio is 24.85%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.